Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
Beatriz Grinsztejn,Mina C. Hosseinipour,Heather J. Ribaudo,Susan Swindells,Joseph J. Eron,Ying Q. Chen,Lei Wang,San San Ou,Maija Anderson,Marybeth McCauley,Theresa Gamble,N. Kumarasamy,James Hakim,Johnstone Kumwenda,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Marineide Gonçalves de Melo,Kenneth H. Mayer,Susan H. Eshleman,Estelle Piwowar-Manning,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Ian Sanne,Joel E. Gallant,Irving F. Hoffman,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Diane V. Havlir,Myron S. Cohen +32 more
Reads0
Chats0
TLDR
The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment.Abstract:
Summary Background Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. H owever, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the eff ects of early and delayed initiation of antiretroviral treatment on clinical outcomes. Methods The HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries. We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either early or delayed antiretroviral treatment by use of permuted block randomisation, stratifi ed by site. Random assignment was unblinded. The HIV-1-infected member of every couple initiated antiretroviral treatment either on entry into the study (early treatment group) or after a decline in CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00074581. Findings 1763 people with HIV-1 infection and a serodiscordant partner were enrolled in the study; 886 were assigned early antiretroviral treatment and 877 to the delayed treatment group (two individuals were excluded from this group af ter randomisation). Median CD4 counts at randomisation were 442 (IQR 373–522) cells per μL in patients assigned to the early treatment group and 428 (357–522) cells per μL in those allocated delayed antiretroviral treatment. In the delayed group, antiretroviral treatment was initiated at a median CD4 count of 230 (IQR 197–249) cells per μL. Primary clinical events were reported in 57 individuals assigned to early treatment initiation versus 77 people allocated to delayed antiretroviral treatment (hazard ratio 0·73, 95% CI 0·52–1·03; p=0·074). New-onset AIDS events were recorded in 40 participants assigned to early antiretroviral treatment versus 61 allocated delayed initiation (0·64, 0·43–0·96; p=0·031), tuberculosis developed in 17 versus 34 patients, respectively (0·49, 0·28–0·89, p=0·018), and primary nonAIDS events were rare (12 in the early group vs nine with delayed treatment). In total, 498 primary and secondary outcomes occurred in the early treatment group (incidence 24·9 per 100 person-years, 95% CI 22·5–27·5) versus 585 in the delayed treatment group (29·2 per 100 person-years, 26·5–32·1; p=0·025). 26 people died, 11 who were allocated to early antiretroviral treatment and 15 who were assigned to the delayed treatment group.read more
Citations
More filters
Journal ArticleDOI
Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines.
Purificación Cid-Silva,Luis Margusino-Framiñán,Vanesa Balboa-Barreiro,Berta Pernas-Souto,Álvaro Mena-de-Cea,Isabel Martín-Herranz,Ángeles Castro-Iglesias,Eva Poveda +7 more
TL;DR: In this article, the authors evaluated the immunological and clinical properties of antiretroviral treatment for all HIV-infected individuals regardless of CD4 count and found that ART initiation is recommended for all patients regardless of their CD4 counts.
Journal ArticleDOI
Assessing the health status and mortality of older people over 65 with HIV.
Gina Turrini,Stephanie S. Chan,Pamela W. Klein,Stacy M. Cohen,Antigone Dempsey,Heather Hauck,Laura W. Cheever,Andre R. Chappel +7 more
TL;DR: It is important for clinicians and policymakers to be aware that older people with HIV have a higher odds of having multiple chronic conditions at any point in time, a higher incidence of new diagnoses of these conditions over time, and a higher hazard of mortality than Medicare beneficiaries without HIV.
Journal ArticleDOI
A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research
TL;DR: Ongoing research and normative deliberation is required in order to successfully and ethically scale-up TasP within the continuum of HIV care models.
Journal ArticleDOI
Early access to antiretroviral therapy versus standard of care among HIV-positive participants in Eswatini in the public health sector: the MaxART stepped-wedge randomized controlled trial
Shaukat Khan,Donna Spiegelman,Donna Spiegelman,Fiona J Walsh,Sikhatele Mazibuko,Munyaradzi Pasipamire,Boyang Chai,Ria Reis,Ria Reis,Ria Reis,Khudzie Mlambo,Wim Delva,Gavin Khumalo,Mandisa Zwane,Yvette Fleming,Emma Mafara,Anita Hettema,Charlotte Lejeune,Ariel Chao,Till Bärnighausen,Till Bärnighausen,Velephi Okello +21 more
TL;DR: This trial was implemented in a government‐managed public health system with the aim to examine the “real world” impact of EAAA on care retention and viral suppression.
Journal ArticleDOI
Positive Strategies to Enhance Problem-Solving Skills (STEPS): A Pilot Randomized, Controlled Trial of a Multicomponent, Technology-Enhanced, Customizable Antiretroviral Adherence Intervention for HIV-Infected Adolescents and Young Adults.
Matthew J. Mimiaga,Laura M. Bogart,Laura M. Bogart,Idia B. Thurston,Christopher M. Santostefano,Elizabeth F. Closson,Margie R. Skeer,Katie B. Biello,Katie B. Biello,Steven A. Safren,Steven A. Safren +10 more
TL;DR: A pilot randomized controlled trial of the Positive STEPS intervention against a standard of care control was conducted and the feasibility of procedures and participant acceptability of the intervention in terms of content, structure, and format was reported on.
References
More filters
Journal ArticleDOI
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
TL;DR: In this article, Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
Journal ArticleDOI
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
Anthony S. Fauci,John G. Bartlett,Eric P. Goosby,M. D. Smith,H. J. Kaiser,S. W. Chang,James M. Anderson,R. Armstead,A. C. Baker,David A Barr,Samuel A. Bozzette,S. Cox,M. Delaney,Fred M. Gordin,W. Greaves,M. Harrington,J. J. Henning,Martin S. Hirsch,J. Jacobs,Richard Marlink,C. Maxwell,J. W. Mellors,D. B. Nash,S. Perryman,Robert T. Schooley,R. Sherer,Stephen A. Spector,G. Torres,Paul A. Volberding,B. A. Brady,E. M. Daniels,D. Feigal,Mark B. Feinberg,H. D. Gayle,T. R. Graydon,Jonathan E. Kaplan,Abe M. Macher,R. F. Martin,Henry Masur,Lynne M. Mofenson,J. Murray,J. O'Neill,L. C. Perez,R. Riseberg,S. Shekar,Sharilyn K. Stanley,J. Whitescarver +46 more
TL;DR: These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation.
Journal ArticleDOI
Prevention of HIV-1 infection with early antiretroviral therapy
TL;DR: The exciting evidence generated by this paper – that antiretroviral treatment of HIV-1 infection definitively reduces the risk of onward transmission of the virus by 96% – was rightly dubbed Science magazine's ‘Breakthrough of the Year’ in 2011.
Journal ArticleDOI
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F. Günthard,Judith A. Aberg,Joseph J. Eron,Jennifer F Hoy,Amalio Telenti,Constance A. Benson,David M. Burger,Pedro Cahn,Joel E. Gallant,Marshall J. Glesby,Peter Reiss,Michael S. Saag,David L. Thomas,Donna M. Jacobsen,Paul A. Volberding +14 more
TL;DR: This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Journal ArticleDOI
Overadjustment bias and unnecessary adjustment in epidemiologic studies.
TL;DR: This work uses causal diagrams and an empirical example (the effect of maternal smoking on neonatal mortality) to illustrate and clarify the definition of overadjustment bias, and to distinguish over adjustment bias from unnecessary adjustment.
Related Papers (5)
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Leslie Cottle,Xinyi C. Zhang,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Sharlaa Faesen,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Sarah E. Hudelson,Andrew D. Redd,Thomas R. Fleming +35 more
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more